U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Advisory Committees
  3. Committees and Meeting Materials
  4. Human Drug Advisory Committees
  5. Oncologic Drugs Advisory Committee
  6. Oncologic Drugs Advisory Committee Roster
  1. Oncologic Drugs Advisory Committee

Oncologic Drugs Advisory Committee Roster

Applying for Membership on FDA Advisory Committees

As part of the Food and Drug Administration (FDA)’s ongoing efforts to recruit qualified experts with minimal conflicts of interest who are interested in serving on advisory committees, FDA requests nominations for members to serve on its advisory committees.

Learn More

Current Number of Vacancies = 6
NOTE: One or more vacancies may be in the nomination process or a final appointment may have been made.

* Consumer Representative (vacant)
** Industry Representative, non-voting

Committee Roster

Chairperson

Ravi A. Madan, MD

Expertise: Genitourinary Oncology
Term: 9/29/2021 – 6/30/2025

Senior Clinician
Head, Prostate Cancer Clinical Research Section
Genitourinary Malignancies Branch
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Building 10, 13N240b
10 Center Drive
Bethesda, Maryland 20892

Acting Designated Federal Officer

Yvette Waples, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, Maryland 20993-0002
Phone: (301) 796-9001
Fax: (301) 847-8533
E-mail: ODAC@fda.hhs.gov

**Tara L. Frenkl, MD, MPH

Expertise: Drug Development, Oncology, Urology, Women’s Health
Term: 1/17/2024 – 10/31/2027

Senior Vice President, Head of Global Medical Strategy and Evidence Generation
Bayer Pharmaceuticals
100 Bayer Boulevard, PO Box 915
Whippany, New Jersey 07981

Toni K. Choueiri, MD

Expertise: Drug Development, Biomarkers, GU Cancers, Solid Tumors
Term: 8/28/2023 – 6/30/2027

Director, Lank Center for Genitourinary Oncology
Professor, Harvard Medical School
Dana-Farber Cancer Institute
450 Brookline Avenue, Dana 929-A
Boston, Massachusetts 02215

Mark R. Conaway, PhD

Expertise: Biostatistics
Term: 7/1/2021 – 6/30/2025

Professor
Division of Translational Research and Applied Statistics
Department of Public Health Sciences
Box 800717 UVA Health System
The University of Virginia School of Medicine
Charlottesville, Virginia 22908

William J. Gradishar, MD

Expertise: Breast Cancer
Term: 8/28/2023 – 6/30/2027

Professor of Medicine/Betsy Bramsen Professor of Breast Oncology
Chief, Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center
Feinberg School of Medicine at Northwestern University
420 E Superior Street
Chicago, Illinois 60611

Pamela L. Kunz, MD

Expertise: Neuroendocrine Tumors, Pancreatic and Gastrointestinal Oncology
Term: 9/29/2021 – 6/30/2025

Associate Professor of Medicine (Oncology)
Division Chief, GI Oncology
Yale School of Medicine and Yale Cancer Center
333 Cedar Street, PO Box 208028
New Haven, Connecticut 06520

Daniel Spratt, MD

Expertise: Prostate Cancer and Surrogate Endpoints
Term: 8/28/2023 – 6/30/2027

Vincent K Smith Chair, Department of Radiation Oncology
Professor of Radiation Oncology and Urology
UH Seidman Cancer Center
Case Western Reserve University
11100 Euclid Avenue
Cleveland, Ohio 44106

Neil Vasan, MD, PhD

Expertise: Breast Cancer, Medical Oncology, Translational Medicine
Term: 7/1/2022 - 6/30/2026

Assistant Professor
Division of Hematology & Oncology
Department of Medicine
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
1130 St. Nicholas Avenue, ICRC/Room 312KA
New York, New York 10032

 

 

 

 

 

 

 

 

 

Back to Top